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Abstract Solid lipid nanoparticles (SLN) without drug
and SLN loaded with chloroaluminum phthalocyanine
(AlClPc) were prepared by solvent diffusion method in
aqueous system and characterized by thermal analyses and
X-ray diffraction (XRD) in this study. Determination of
particle size, zeta potential (ZP), and encapsulation effi-
ciency were also evaluated. SLN containing AlClPc of
nanometer size with high encapsulation efficiency and ZP
were obtained. The results indicated that the size of SLN
loaded with AlClPc is larger than that of the inert particle,
but ZP is not changed significantly with incorporation of
the drug. In differential scanning calorimetry (DSC)
curves, it was observed that the melting point of stearic
acid (SA) isolated and in SLN occurred at 55 and 64 C,
respectively, suggesting the presence of different poly-
morphs. DSC also shows that the crystallinity state of SLN
was much less than that of SA isolated. The incorporation
of drug in SLN may have been favored by this lower
crystallinity degree of the samples. XRD techniques
corroborated with the thermal analytic techniques, sug-
gesting the polymorphic modifications of stearic acid.
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Introduction
Photodynamic therapy is a non-surgical, minimally inva-
sive approach, which has been used in the treatment of
superficial epithelial tumors such as oral squamous carci-
nomas and non-melanoma skin cancer [1–3]. The therapy
is based on the photoactivation of a photosensitizer (PS)
when irradiated by light in a specific wavelength window
(generally the maximum absorption band of the PS com-
pound). The light-excited PS generates reactive oxygen
species (ROS) that induce reduction or destruction of
tumors by multifactorial mechanisms [4].
Among the various PS drugs investigated, phthalocya-
nines have been found to be highly promising [1, 2, 5].
Phthalocyanines present a variety of metal ions in their
chemical structure, which are indeed responsible for the
particular property of each molecule. Aluminum (III) is a
metal ion used for enhancing phthalocyanine phototoxicity
[2, 6]. However, most phthalocyanines are hydrophobic
compounds requiring association to specific drug delivery
systems for clinical use.
Solid lipid nanoparticles (SLN) are alternative colloidal
carrier systems for controlled drug delivery with a mean
diameter between approximately 50 and 1,000 nm, which
presents some advantages when compared with other par-
ticulate carriers, such as a good tolerability and bio-
degradation, a high bioavailability, a targeting effect,
encapsulation of a poorly water soluble drug, and no
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problems with respect to large scale production and ster-
ilization [7, 8]. However, as for all drug delivery systems,
detailed characterization is a major part of the research and
development work on lipid nanoparticle dispersions to
ensure the generation of systems with the desired proper-
ties. Among several analytic techniques employed for this
purpose, differential scanning calorimetry (DSC) and
X-ray diffraction (XRD) play a prominent role because
they are able to provide structural information on the dis-
persed particles, and they have been employed to investi-
gate the crystalline structure of SLN and the drug [9–12].
Moreover, the use of these two techniques often leads to
complementary information on the systems of interest.
The aim of this study was to prepare chloroaluminum
phthalocyanine (AlClPc)-loaded SLN for photodynamic
therapy of non-melanoma skin cancer using stearic acid
(SA) as solid lipid and to characterize these systems by
DSC, TG/DTG, and XRD techniques. Particle size,
entrapment efficiency (EE), drug loading (DL), and zeta
potential (ZP) of SLN were also evaluated.
Materials and methods
Materials
AlClPc was acquired from Aldrich Chemical Company.
SA was purchased from VETEC (Brazil). All the other
solvents and reagents obtained were of analytic grade.
Preparation of SLN
SLN containing AlClPc and inert SLN (without drug) were
prepared by solvent diffusion technique in an aqueous
system using SA as solid lipid according to the modified
method earlier described by Hu et al. [13]. In brief, SA and
drug (AlClPc) were completely dissolved in ethanol
(3 mL) in a water bath at 70 C. The resultant organic
solution was quickly dispersed into 120 mL of sodium
lauryl sulfate (SDS) aqueous solution (2%, w/w)
warmed to 70 C under magnetic stirring. The obtained
pre-emulsion (melted lipid droplet) was then cooled at
room temperature until drug-loaded SLN dispersion was
obtained. After 24 h, under continual stirring for solvent
evaporation, SLN was cooled to 4 C to enable aggregation
of nanoparticles. The aggregate of nanoparticle dispersion
was then centrifuged (5,000 rpm for 1 h to 4 C, 5804R
Model, Eppendorf). The precipitate of SLN was redi-
spersed into SDS aqueous solution (0.2%, w/w) to remove
the drug adsorbed on the surface of lipid nanoparticles.
Then, the AlClPc-SLN was collected by centrifugation at
5,000 rpm for 15 min, the precipitate was frozen, and then
the sample was moved to the freeze–drier. SLN prepared
with drug:lipid at different proportions w/w were obtained
(Table 1). Inert SLN were prepared by the same procedure.
Determination of particle size and zeta potential
The particle size and ZP of the resulting AlClPc-SLN were
measured by Zetasizer (Malvern Instruments, UK). For the
preparation of samples, the SLN dispersions were diluted
30 times with distilled water.
Determination of drug entrapment efficiency (EE)
and drug loading (DL)
The contents of AlClPc in the two supernatants, removed
as mentioned in the method of SLN preparation, were
measured by fluorescence spectroscopic technique. First,
supernatant was separated after the SLN dispersion was
centrifuged. Another supernatant was separated after the
SLN were washed by 0.2% SDS solution (w/w) and cen-
trifuged again. The drug EE and DL of AlClPc-loaded SLN
were then calculated from formulas 1 and 2:
DL ¼ ðWT  WS1  WS2ÞðWT  WS1  WS2  WLÞ  100% ð1Þ
EE ¼ ðWT  WS1  WS2ÞðWT)  100% ð2Þ
where WT was the total amount of charged drug. The drug
content in aqueous solution was taken into account in the
calculation of the EE and DL of SLN. WS1 was the amount
Table 1 Particle size, polydispersity index (PDI), entrapment efficiency (EE), drug loading (DL), and zeta potential (ZP) of stearic acid (SA) in
SLN
SLN AlClP/mg Stearic
acid/mg
SDS/w/w% Entrapment
efficiency/%
Drug
loading/%
Size/nm Zeta potential/mV PDI
Inert SLN – 190 2 – – 142.7 -54.8 0.49
SLN 1 5 100 2 79.01 4.75 639.3 -50.7 0.79
SLN 2 5 190 2 85.78 2.50 255.1 -57.0 0.67
SLN 3 5 250 2 71.61 1.96 218.9 -56.8 0.48
SDS sodium lauryl sulfate
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of drug in the supernatant after the first centrifugation,
WS2 was the amount of drug in the supernatant after the
second centrifugation, and WL was the total amount of
charged lipid [14].
The quantification of AlClPc encapsulated was carried
out according to a validated methodology based in fluo-
rescence spectroscopic technique. Samples were excited at
375 nm, and the AlClPc concentrations were measured
from the standard curve. Linearity was achieved over the
concentration range between 0.01 and 0.2 lg/mL, pre-
senting a correlation coefficient (R) of 0.998. These values
are considered adequate for an analytic method. Parameters
such as precision, accuracy, and limit of quantification
were also evaluated.
Thermal analysis
DSC curves of pure SA, inert SLN, isolated drug, and
AlClPc-loaded SLN were obtained in a DSC-50 cell
(Shimadzu) using aluminum crucibles with samples of
about 2 mg, under dynamic nitrogen atmosphere (50 mL/
min) and heating rate of 10 C/min in the temperature
range from 25 to 600 C. The DSC cell was calibrated with
indium (m.p. 156.6 C; DHfus. = 28.54 J/g), conforming to
ASTM standards [15].
TG/DTG curves of pure stearic acid, inert SLN, AlClPc,
and AlClPc-loaded SLN were obtained with a thermobal-
ance model TGA 50 (Shimadzu) in the temperature range
of 25–900 C, using platinum crucibles with samples of
about 3 mg, under dynamic nitrogen atmosphere (50 mL/
min) and heating rate of 10 C/min. The TG/DTG was
calibrated with calcium oxalate monohydrate, conforming
to ASTM standards.
X-ray diffraction
X-ray diffraction measurements were performed to clearly
elucidate the solid state of lipid and drug in SLN using an
X-ray diffractometer (Rigaku, Rint/2000 Model). The
X-ray diffractogram was scanned with the diffraction angle
increasing from 3 to 40, 2h angle, at speed 2/min, and at a
constant temperature of 25 C.
Results and discussion
Particle size and zeta potential
The SLN were characterized to assess the effect of the
different proportions of lipid and drug on mean particle
size, size distribution, and surface charge. The particle size
and polydispersity index (PDI) of the SLN obtained are
reported in Table 1. It was possible to obtain submicron-
sized SLN with all lipid:drug proportions. In fact, SLN
showed a mean diameter in the range of 142–639 nm. The
PDI value was in the range of 0.48–0.79 for all the SLN
investigated. These values can be considered high for use
on routes, such as parenteral, but are acceptable for topical
applications. There was an increase in particle size when
formulated with AlClPc. Inert SLN presented a mean
diameter of about 142 nm, while SLN containing AlClPc
presented mean diameters in the range of 218–639 nm. Hu
et al. [13, 16] found similar results for SA in the SLN,
where incorporation of a lipophilic model drug, Clobetasol
Propionate, resulted in a significantly increased size of the
SLN studied.
Zeta potential (ZP) can make a prediction about the
stability of colloid dispersions. A high ZP ([±30 mV) can
provide an electric repulsion to avoid the aggregation of
particles [16, 17]. The ZPs of the SLN obtained are also
listed in Table 1. The incorporation of AlClPc into lipid
nanoparticles had weak influence on the ZP of the particles,
which was about -50 mV in all the cases. This demon-
strates that the nanoparticle dispersion obtained by solvent
diffusion method in an aqueous system is a physically
stable system in this study.
Drug entrapment efficiency and drug loading
Table 1 also shows the results of entrapment efficiency
(EE) and DL for the SLN obtained. The EE and DL of SLN
were from 71 to 85% and from 1.96 to 4.75%, respectively.
Several authors correlate the encapsulation efficiency with
the crystallinity degree of the samples. Previous studies
have shown that the greater the disorganization of the
crystalline matrix of the system obtained, the greater the
drug encapsulation ability [9, 13, 18]. Thus, techniques of
thermal analysis and X-ray diffraction were employed to
evaluate these changes.
An important point to be considered in the character-
ization of SLN is the potential occurrence of different
polymorphic forms [19]. The different molecular packing
in the polymorphic modifications is reflected in differences
of physical properties like the melting points and enthal-
pies. In general, the production process of the nanoparticles
can change the type of polymorph [9, 19]. Fatty acids like
SA, which are usually employed for the preparation of the
corresponding systems, can exist in four different poly-
morphic forms namely A, B, C, and E [20, 21]. All these
forms can be obtained upon crystallization from solution,
but it is believed that only the C form grows upon crys-
tallization from the melt. This form has also been found
with DSC and X-ray diffraction in (dried) SA nanoparticle
preparations [9, 22, 23].
Preparation and characterization of chloroaluminum phthalocyanine 193
123
Then, SA, AlClPc, and SLN obtained in this study were
analyzed by DSC and TG/DTG (Figs. 1 and 2). Table 2
shows the corresponding DSC data for the melting point of
SA. To produce SLN, the lipid is melted, the drug is dis-
solved in the melted lipid, and then this drug-containing
melt is dispersed in a hot surfactant solution to yield a pre-
emulsion. Cooling leads to crystallization of the lipid and
formation of SLN. The melting point of SA was 55 C for
isolated solid lipid close to the event mentioned in the
literature for polymorph B (54 C) [24]. In order to dif-
ferentiate between the actual effect of the SLN production
process and the effect of the AlClPc, inert SLN (without
drug) were also prepared and analyzed. According to data
presented in Fig. 1 and Table 2, crystallization of SLN
during the preparation method promoted a polymorphic
modification of the lipid particle matrix. The melting point
temperature of SA in inert SLN was shifted to the tem-
perature of 64 C, suggesting the presence of C polymorph,
which is thermodynamically the most stable form and may
be obtained by solidification of the melt and sometimes by
crystallization from a polar solvent [22, 24]. Garti et al.
[24] also showed that the crystallization of SA from a non-
polar solvent usually gives either the A form or a mixture
of the B and C forms. Moreover, Aquilano et al.
[22] showed that solid lipospheres prepared with SA,
co-surfactant (solvent), and surfactant has resulted in the
formation of C polymorph, although B polymorph was also
present in some samples. The presence of B polymorph
was dependent on the concentration of co-surfactant used
(butanol). In Fig. 1, it is observed that C polymorph is
present predominantly in all the nanoparticle samples
(64 C). Figure 1 shows another event at 55 C for all the
SLN, and one event at 45 C for inert SLN and SLN 1.
Compared to the literature data, these events seem to cor-
respond to phase transition of B polymorph and dehydra-
tion (water associated to nanoparticles), respectively [24].
This dehydration is also shown in the TG/DTG curve
(Fig. 2) where a water loss was verified for all the SLN.
It is also seen in Table 2 that the enthalpy of SA in the
SLN was reduced relative to that of lipid alone. As a result,
it can be concluded that the lipid within the nanoparticles
presented lower crystallinity degree compared with pure
SA. Several factors can influence the crystallinity degree,
such as lyophilization and the presence of drug and sur-
factant [18, 25]. Li et al. [18] observed that there was a
sharp decline in the enthalpy from the pure lipid to the
nanoparticles. For less-ordered crystals or amorphous sol-
ids, the melting of the substance requires much less energy
than crystalline substances that need to overcome lattice
forces. Thus, those authors concluded that the lipid within
the nanoparticles should be in a less-ordered arrangement
when compared to the pure lipid. This can indicate that the
crystallinity degree of lipid matrix in SLN was lower than
that of SA isolated.
On comparing the DSC curves obtained from inert SLN
with AlClPc-loaded SLN, it can be observed that the
concentration of drug and of SA in relation to SDS solution
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Fig. 1 DSC curves of AlClPc, SA, inert SLN, AlClPc-loaded SLN in
dynamic nitrogen (50 mL/min), and heating rate of 10 C/min
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Fig. 2 TG/DTG curves of AlClPc, SA, inert SLN, AlClPc-loaded
SLN in dynamic nitrogen (50 mL/min), and heating rate of 10 C/min
Table 2 Onset temperature, melting point (peak maximum), and
melting enthalpy of stearic acid in SLN with and without drug
SLN Peak
maximum/C
Tonset/C Melting
enthalpy/J/g
Stearic acid 55.6 47.3 -167.2
Inert SLN 64.3 59.5 -48.0
SLN 1 64.1 58.5 -47.2
SLN 2 65.3 60.0 -77.2
SLN 3 64.0 58.5 -65.6
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affected the enthalpy and, consequently, the crystallinity
degree. In general, the crystallinity degree of the lipid
matrix in SLN provides useful information about its
behavior in the incorporation of drugs. That is, an ideal
formulation of SLN should present a lower degree of
crystallinity, increasing the DL and avoiding the drug
expulsion after melting and recrystallization [18]. A high
value of enthalpy of fusion suggests high organization in
the crystal lattice because the fusion of a highly organized
crystal requires more energy to overcome the forces of
cohesion in the crystal lattice than that is required in a
crystal less ordered or amorphous [18].
Indeed, SLN with the highest DL also had lesser
enthalpy and a lower degree of crystallinity, and seem to be
the most appropriate delivery system for incorporating
AlClPc. Hu et al. [13] also found similar results for lipid
nanoparticles of SA containing clobetasol propionate.
However, the highest enthalpy and melting point was for
SLN 2, which presents a DL of 2.5% at the concentration
of 190 mg of SA in 120 mL of 2% SDS solution (w/w).
This suggests that the final proportion of SA and surfactant
(SDS) in lyophilized nanoparticles (amount of impurity)
also significantly influences the degree of crystallinity of
the samples.
TG curve of SA (Fig. 2) showed two events of mass loss
relative to the thermal decomposition (Tpeak DTG = 296.9 C
e Dm = 95.13%) followed by elimination of carbonaceous
material. AlClPc presented a thermal event at 157.2 C in
DSC curve, which was accompanied by a mass loss
(Dm = 6.2%) observed by TG/DTG curves probably
because of volatiles evaporation (N2, O2, CO2, and H2O) or
low-temperature degradation of unstable chemical frag-
ments in the samples. Inert SLN showed a two-step mass
loss. The first event occur Tpeak DTG = 359.3 C corre-
sponding the loss of Dm = 75.1%; in the second event Tpeak
DTG = 416.5 C is observed a mass loss of Dm = 3.81%.
As shown in Fig. 2, the mass loss (%) of free SLN 1 at
the heating rate of 10 C/min can be divided into four
consecutive processes. The sample in first stage is in the
temperature range from 25 to 80 C with a Dm of 1.0%,
which is due to the release of water molecules from the
outside or/and inside of nanoparticles. Subsequently, the
sample in the second stage is kept in a very wide temper-
ature range, i.e., from 177.7 to 265.1 C (Dm = 17.6%).
Then, the sample in the third stage undergoes a rapid
decomposition (Dm = 58.76%). During continuous heat-
ing, the sample in the last stage is carbonized
(Dm = 1.7%). Thermal behaviors of the SLN 2 and SLN 3
were very similar to each other. TG curves presented a
characteristic profile of elimination of water surface
between 35 and 80 C, with thermal stability between 100
and 160 C, following thermal decomposition with
carbonization.
X-ray diffraction (XRD) was employed to investigate
the crystalline structure of SLN and the drug. Diffracto-
grams of SLN, AlClPc, and SA are displayed in Fig. 3. The
diffraction curve of SA shows differences from those of
SLN. Compared with the pure lipid, the peak intensities of
SLN without drug are much weaker, which indicates that
the SA is presented in a less crystalline form in these
samples. Thus, the results seem to indicate that SA in SLN
was partially recrystallized or less ordered, as observed
previously by the DSC. The diffractograms of SA exhibit
sharp peaks at 2h scattered angles of 7.07, 20.60, 21.71,
and 24.05, indicating the lipid crystalline nature. The
diffractograms of inert SLN exhibit small peaks at 2h
scattered angles of 6.48, 20.97, 21.71, 22.23, and 24.12,
showing some different XRD patterns (Fig. 3). These
changes are because of the presence of a mixture of
polymorphs in the nanoparticles and the method of
obtaining the SLN. It can also be seen that the diffracto-
grams of SLN after the addition of AlClPc had minor
changes. The diffractograms of SLN containing drug
exhibited small peaks at 2h scattered angles of 6.56, 21.04,
22.06, and 24.19 for SLN 1; 6.56, 21.08, 21.59, 22.09, and
24.12 for SLN 2; and 6.56, 21.12, 21.63, 22.21, and 24.19
for SLN 3. The low intensity of peaks makes it difficult to
distinguish events related to each polymorph, compared to
the available data in the literature. Also, peaks of AlClPc
could not be observed in these diffractograms. Compared
with the pure lipid, the peak intensities of SLN are much
weaker, which indicates that the SA is presented in a less
crystalline form in these samples. Thus, the results seem
to indicate that SA in SLN was partially recrystallized or
less ordered, as observed previously by the DSC and TG/
DTG.
Combining the DSC and XRD data, it can be concluded
that there was a change in the crystalline structure of SA in
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Fig. 3 X-ray diffractograms of AlClPc, SA, inert SLN, and AlClPc-
loaded SLN
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the SLN, suggesting polymorphic modification of the lipid
particle matrix. Besides this, the method of production of
SLN did not favor the total crystallization of the samples,
which may be related to the high encapsulation efficiency
obtained.
Conclusions
Solvent diffusion technique was successfully employed to
prepare the SLN. The experimental results reveal that drug-
loaded SLN presented nanometer size and high encapsu-
lation efficiency, and ZP. DSC and XRD experiments
showed that there was a change in the crystalline structure
of SA in the SLN, suggesting polymorphic modification.
The lipid in SLN is also less ordered, and the lower crys-
tallinity degree of the lipid matrix seems to be related to the
high encapsulation efficiency obtained.
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